GlaxoSmithKline PLC
LSE:GSK
GlaxoSmithKline PLC
LSE:GSK
Price:
1 716.5 GBX
0.67%
Updated:
May 2, 2024
GlaxoSmithKline PLC
Cash from Financing Activities
|
GlaxoSmithKline PLC
Cash from Financing Activities Peer Comparison
Comparables:
AZN
VRNA
INDV
HIK
DPH
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Financing Activities
-£5.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Financing Activities
-$6.6B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-8%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Cash from Financing Activities
$92.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Cash from Financing Activities
-$46m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Financing Activities
-$337m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cash from Financing Activities
£316.5m
|
CAGR 3-Years
39%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
See Also
What is GlaxoSmithKline PLC's Cash from Financing Activities?
Cash from Financing Activities
-5.6B
GBP
-5.6B
GBP
Based on the financial report for Dec 31, 2023, GlaxoSmithKline PLC's Cash from Financing Activities amounts to -5.6B GBP.
What is GlaxoSmithKline PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
1%
1%
The average annual Cash from Financing Activities growth rates for GlaxoSmithKline PLC have been 18% over the past three years , 2% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
